BRAF and melanoma: Indeed, they found in a zebrafish xenograft model that BRAF inhibitor‐pretreated melanoma cells, expressing elevated MITF levels, are not only more resistant to BRAF inhibition themselves, but also decrease the sensitivity to BRAF inhibition of untreated cells.